Friday, October 16, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 27, 2026

Convocation de l’assemblée générale annuelle d’approbation des comptes 2025 prévue le 22 mai 2026 et évolution du conseil d’administration d’Atos

View original at globenewswire.com
Convocation de l’assemblée générale annuelle d’approbation des comptes 2025 prévue le 22 mai 2026 et évolution du conseil d’administration d’Atos Communiqué de presse Convocation de l’assemblée générale annuelle d’approbation des comptes 2025 prévue le 22 mai 2026 et évolution du conseil d’administration d’Atos Paris,…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Board of Directors decided to maintain the combined Chairman and CEO roles exercised by Philippe Salle if his director mandate is renewed

    60% confidence

  • Not proposing renewal of Mandy Metten's censeure mandate aligns with best governance practices and reflects that the position enabled transition after her employee representative director term

    60% confidence

  • Laurent Collet-Billon brings particularly relevant strategic perspective to the Board for the Group's activities based on his recognized experience in defense, security and digital sectors, notably as head of DGA

    60% confidence

  • The mandate renewals would ensure governance continuity and recognize the commitment, experience and valuable contributions of Philippe Salle and Laurent Collet-Billon to the Board's work and the Group's transformation

    60% confidence

  • Philippe Salle brings key competencies to the Board to continue implementing the strategic plan and transformation while ensuring governance continuity and stability, based on his experience leading public companies and understanding the Group's strategic, operational and financial challenges

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com